Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04016870
Other study ID # HUM00050238
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date October 13, 2018
Est. completion date October 2024

Study information

Verified date September 2023
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lack of access to pacemakers is a major challenge to the provision of cardiovascular health care in Low and Middle Income Countries (LMIC). Post-mortem pacemaker utilization could be safe, efficacious, and ethically responsible means of delivering the needed care. Reconditioned pacemakers can provide therapy for patients with symptomatic bradycardia and no means of receiving a new device. The objective of the clinical trial is to determine if pacemaker reutilization can be shown to be a safe means of delivering pacemakers to patients in LMIC without resources. Consented patients in this multi-center trial will be randomized to undergo implantation of either a reconditioned device or a new device.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 260
Est. completion date October 2024
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Life expectancy = 2 years. - Indications for device implantation must be fulfilled per standard of care. Consistent with 2008 American College of Cardiology / American Heart Association guidelines for device therapy, one of the following class I indications must be met. - Sinus Node Dysfunction - Acquired Atrioventricular (AV) Block - Chronic Bifascicular Block - Hypersensitive Carotid Syndrome - Lack of financial ability to pay for a new device must be assessed and documented. - All other methods of new device acquisition must be exhausted. - Patient must be agreeable and able to follow-up with the implanting center within 2 weeks for wound check, at 2 months, 6 months, and every 6 months thereafter for routine pacemaker checks. Exclusion Criteria: - Severe valvular disease - Severe pulmonary disease - End-stage renal disease (creatinine clearance < 30 mL/min) whether or not on dialysis - Evidence of ongoing systemic infection - Prior pacemaker or implantable cardioverter-defibrillator implantation - Significant contraindication to pacemaker implantation per evaluation of the implanting physician (very high risk of complications). - Presence of any other condition that the local investigator feels would be problematic or would restrict or limit the participation of the patient for the entire study period - Pregnant women

Study Design


Intervention

Device:
Reconditioned Pacemaker
Devices from the three manufacturers below will be used.
New Pacemaker
Devices from the four manufacturers below will be used.

Locations

Country Name City State
Kenya The Moi Teaching and Referral Hospital Eldoret
Nigeria LASUTH Ikeja Lagos
Nigeria Port Harcourt Teaching Hospital Port Harcourt Rivers
Paraguay FUNDACOR Asunción
Sierra Leone Choithram Memorial Hospital Freetown
Venezuela ASCARDIO Barquisimeto Lara

Sponsors (1)

Lead Sponsor Collaborator
University of Michigan

Countries where clinical trial is conducted

Kenya,  Nigeria,  Paraguay,  Sierra Leone,  Venezuela, 

Outcome

Type Measure Description Time frame Safety issue
Primary Freedom from Procedure-Related Infection at 12 months Clinical evidence of pacemaker infection includes local signs of inflammation at the generator site such as erythema, warmth, fluctuance, tenderness, purulent drainage, wound dehiscence, or erosion. Device related endocarditis will be reported if the Duke criteria for infective endocarditis are met. Procedure-related infections will be classified as follows: pocket infection, endocarditis, recurrent bacteremia, extrusion of wires or generator 12 months post device implantation
Secondary Freedom from Pacemaker Software or Hardware Malfunction at 12 months Pacemaker software or hardware malfunction include unexpected premature battery depletion, device or electrode malfunction, or unexplained patient death. 12 months post device implantation
See also
  Status Clinical Trial Phase
Completed NCT03922386 - Safety and Electrical Performances of XFINE Leads N/A
Completed NCT03294018 - Heart Rate Changes Following the Administration of Sugammadex
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Not yet recruiting NCT05440071 - PoSt-market Assessment on Safety and Performance of J-sHAPed xFINE Lead
Completed NCT02153242 - The Effects of Selective Site Right Ventricular Pacing
Recruiting NCT01825473 - Study of Erythromycin in GER-Associated Apnea of the Newborn N/A
Completed NCT00950287 - Detection of Neonatal Bradycardia N/A
Completed NCT00721136 - Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation N/A
Completed NCT00286858 - Beluga - Clinical Observations of Automatic Algorithms for Cardiac Pacing
Completed NCT00158925 - The EASYTRAK EPI Clinical Investigation Phase 3
Completed NCT00180557 - Austria Study - Analysis of Difference Between Active and Passive Fixation Leads Phase 4
Completed NCT01076348 - Model 4965 Post-Approval Study
Completed NCT04198220 - BIO|STREAM.ICM Obesity
Recruiting NCT05298748 - The Effect of Womb Recordings on Maturation of Respiratory Control in Preterm Infants N/A
Recruiting NCT04353960 - The Alaska Oculocardiac Reflex Study
Terminated NCT04093414 - Left Bundle Area Versus Selective His Bundle Pacing N/A
Completed NCT03786640 - Abbott Brady 3T MRI PMCF
Recruiting NCT05935007 - Aveir DR Real-World Evidence Post-Approval Study
Recruiting NCT05932602 - AVEIR DR Coverage With Evidence Development (CED) Study
Recruiting NCT04075084 - Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)